GoToMeeting and call-in information below:
Please join my meeting from your computer, tablet or smartphone.
You can also dial in using your phone. United States: +1 (646) 749-3112 Access Code: 304-220-821
First GoToMeeting? Try a test session: http://help.citrix.com/getready
The NIMH Division of AIDS Research (DAR) presents:
Jared Baeten, MD, PhD
Vice Chair, Department of Global Health
Professor, Departments of Global Health, Medicine, and Epidemiology
Director, UW/Fred Hutch Center for AIDS Research (CFAR)
Co-Director, International Clinical Research Center
University of Washington
PrEP for HIV Prevention in Africa:
From Clinical Trials to Implementation
Friday, April 21st, 2017
10:30 am – 12:00 pm
Speaker: Dr. Jared Baeten led the Partners PrEP Study, one of two PrEP trials that resulted in the first FDA approval of a medication for the prevention of HIV acquisition in adults. Dr. Baeten followed the Partners PrEP Study with a multidisciplinary, implementation science study of PrEP and antiretroviral therapy for HIV prevention among East African HIV serodiscordant couples (the Partners Demonstration Project), an ongoing national roll-out of PrEP for couples in Kenya (the Partners Scale-Up Project), and projects to deliver PrEP to young women at risk.
Presentation Overview: In 2010-2011, pivotal clinical trials demonstrated for the first time that antiretroviral medications, used as pre-exposure prophylaxis (PrEP), could significantly and safely reduce the risk of HIV acquisition in persons at risk of HIV. The past six years have seen substantial advances in PrEP, including demonstration studies proving that effective delivery of PrEP in a variety of settings is possible, research to understand best practices for PrEP provision, and normative guidance on how to deliver PrEP. PrEP is a new prevention tool and it both fits within HIV prevention and treatment paradigms but also goes beyond those: a biomedical intervention (a pill, or other approaches) that requires specific behaviors for successful and safe use (HIV testing, interaction with the health system, perception of risk, adherence), operating in a diverse social context (sex, stigma, relationships, power, gender), and depending on public health and public policy (costs, trade-offs, legal frameworks). Choice – of when to use PrEP, of when to stop PrEP, and what type of PrEP to use – will be key to achieving impact. PrEP offers real promise for reducing HIV infections globally; it also forces us to think differently, about HIV, about sexuality, and about prevention.